glp 1 agonist crohn's disease The Potential for GLP-1s in the Treatment of GLP-1R Agonists and Their Therapeutic

In West Virginia, the Public Employees Insurance Agency (PEIA) started a 1,000 person pilot program that covered GLP-1s to treat obesity beginning in 2019

For some patients, particularly those going through hormonal changes, combining GLP-1s with hormone replacement therapy may optimize both weight loss and body composition

Recent findings from studies on humans and animals demonstrate that GLP-1R agonists can also modulate the stress response via HPA axis activation but data obtained so far are ambiguous

Methods We obtained the data from PubMed, Scopus, Embase, and Web of Science for all eligible studies, including clinical trials (RCT) and cohorts comparing GLP-1 RAs to placebo or other hypoglycemic agents in patients with HFpEF published until December 31st, 2024

And how does their staying power turn into effects like lower risk of stroke or improved osteoarthritis

doi:10.1038/eye.2014.144 36